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Sary The need for sample size calculations is briefly reviewed: many of the arguments against small
trials are already wel known, and we only cursorily repeat them in passing. Problems that arise in the
estimation of sample size are then sed, with particular to survival studies. However, most of
the issues which we discuss are equally applcable to other types of study. Finally, prognostic factor analysis
designs are sed, since this is another area in which shows that far too many studies are of an
inadequate size and yield ding results.
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Power and --Aficamce tes
In a clinical trial two or more forms of therapy may be
compared. However, patients vary both in their baseline
characteristics and in their response to therapy. In a clinical
trial, an apparent difference in treatments may be observed
due to chance alone, and this need not n ssarily icate a
true difference due to the use of different treatments. There-
fore it is customary to use a 'signii test' to assess the
weight of evidence and to estimate the probability that the
observed data could in fact have arisen purely by chance.
The results of the signifin test will be expressed as a
'P-value'; for example, P<0.05 would indicate that so ex-
treme an observed difference could be expected to have arisen
by chance alone less than 5% of the time, and so it is quite
likely that a treatment difference really is present.
However, if only a few patients were entered into the trial
then, even if there really is a true treatment difference, the
results are likely to be less convincing than if a much largr
number of patients had been assessed. Thus, the weight of
evidence in favour of concluding that there is a treatment
effect will be much less in a small trial than in a large one. In
particular, if a clinical trial is too small it will be unlikely
that one will obtain sufficiently convincing evidence of a
treatment difference, even when there really is a difference in
efficacy of the treatments; small trials frequently conclude
'there was no significant difference', ir ive of whether
there really is a treatment effect or not. In statistical terms,
we would say that the 'sample size' is too small and that the
'power of the test' is very low.
The 'power' of a signince test is a measure of how
lkely a test is to produce a statistically significant result,
given a true difference between treatments of a certain mag-
nitude.
Effect of same size po of
Suppose the results of a treatment difference in a clinical trial
are declared 'not stastically signiint'. Such a statement
only indicates that there was insufficient weight of evidence
to be able to declare that the observed data are unlikely to
have arisen by chance. It does not mean that there is 'no
clinially important difference between the treatments'. If the
sample size was too small, as discussed in the previous
paragraph, the study might be very unlikely to obtain a
significnt P-value even when a clinically relevant difference
is present. Hence, it is of crucial importance to consider
sample size and power when interpreting statements about
'non-significant' results. In particular, if the power of the test
was very low, all one can conclude from a non-significnt
result is that the question of treatment differences remains
unresolved; the study has provided little information of
value. This has led some authors (e.g. NewelL 1978; Altman,
1980) to question whether studies with a too small sample
size may be scientifically useless and hence an unethical use
of subjects and other resources. Clarly, where possible, it is
wise to aim at conducting a realistically sized trial. However,
the role of small trials in scientific research remains impor-
tant, albeit controversial, and we shall return to this issue
below.
Examle
In 1985 the UK Medical Research Council (MRC) designed
a randomised clinical trial (STOI) which compared two types
of surgery for operable gastric cancer. The aim of this trial
was to compare conventional surgery (RI), as widely prac-
tised in the West, with radical surgery including extended
lymph node dissection (R2), which is commonly practised in
Japan. The principal end point of interest was survival;
reports from Japan showed that patients undergoing R2
surgery had appreciably longer survival durations than those
experienced by patients in other countries, and attributed the
difference to the surgery. Since R2 surgery is far more exten-
sive and aggressive than RI, increased post-operative
morbidity and possibly mortality would have to be offset by
reasonably lar survival advantages for R2 to be worth-
while.
Based upon past experience, it was estimated that the
baseline survival rate of patients undergoing an RI resection
would be 20% at 5 years. The surgeons also thought that R2
surgery might offer appreciable benefits, and a 14% improve-
ment, to 34%, was thought realistic and worthwhile. It was
decded that a P-value of P<0.05 would be an acceptable
'significance level' for the test.
Thus, if a P-vahle of P<0.05 were obtained, we would be
able to declare that such extreme data are unlilkely to be due
to chance, and that we believe there really is a treatment
difference due to surgery; to be more precise, we would only
expect such extreme results in one trial out of 20 (5%) purely
by chance, and thus we would assume that R2 is more
effective than RI.
Calculations show that 400 patients (185 per treatment
arm, which was rounded up to 200) are required for a 90%
power (Machin and Campbell, 1987). This indicates that, if
R2 does improve survival by 14%, we would be 90% certain
of obtaining a signifi level of P<0.05; conversely, 10%
of the time we would fail to obtain a 'sificant' P-value (P
not less than 5%), despite R2 being 14% better than RI.
Sometimes this is described as a 10% false-negative rate. If
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fewer patients were entered. we would be less likely to obtain
a 5% P-value; thus 200 patients (100 per arm) would provide
a power of 66%. In such circumstances, one-third of such
trials could be expected to yield false-negative results. Such a
low power is generally regarded as unacceptable. In most
contexts, 80% is a realistic lower limit for power.
In 1993 the STOl gastric cancer trial completed its
intended patient accrual of 400 patients and the final results
are awaited with interest.
Size of cancer trials
It has long been recognised that many randomised clinical
trials comparing therapies are unrealistically small. In 1978
Freiman et al. examined 110 'negative' trials, constituting
approximately a third of all randomised controlled trials
published in 20 different medical journals. Of these, 71 trials
made explicit statements such as 'No significant reduction in
mortality'. However, Freiman et al. showed that half of these
trials had a power of less than 60% to detect a therapeutic
benefit as large as 50%. They commented 'The conclusion is
inescapable that many of the therapies discarded as
ineffective after inconclusive 'negative' trials may still have a
clinically meaningful effect'.
Yusut et al. (1984). in a paper entitled 'Why do we need
some large and simple randomised trials?'. argued that for
many new treatments, in many disease areas, it is only plausi-
ble to anticipate at best a relative mortality reduction of
15%; furthermore, especially in common diseases. even such
modest mortality reductions are worth detecting since they
imply the saving of many lives. Results from cancer trials
over the decade since that paper strongly support the con-
clusion that in cancer, too, a major treatment breakthrough
is frequently little more than a dream. The reality is that
most therapeutic advances represent small steps, although
collectively they may contribute to a larger overall improve-
ment in survival. Few trials have demonstrated a mortality
reduction as large as 15%.
Yusuf et al. also showed that the implication of this is that
frequently trials ought to aim to enter many thousands of
patients, and that even 2000 may be inadequate, although 'in
real life, of course, the situation is even worse than this, as
the average trial size is probably nearer to 200 than to 2000
patients!'. However, it is important to note that their paper
relates to 'large, simple randomized trials of the effects on
mortality of various widelv practicable treatments for common
conditions'. This is often overlooked, although Freedman
(1989) discussed areas in cancer research in which smaller
trials (fewer than 1000 patients) would still be appropriate.
These included common cancers with a high mortality rate,
in which aggressive therapy would have to yield major sur-
vival improvements for the toxicity disadvantages to be out-
weighed, and areas where large tnrals are not feasible (rare
cancers; treatments which can only be given in specialist
centres). Over the years there has indeed been a gratifying
increase in the average size of trials carried out by the
principal clinical trials offices. For example, before 1990 the
MRC Cancer Trials Office had conducted no tnrals with more
than 1000 patients, whereas currently there are cancer
therapy trials in colorectal cancer (AXIS trial, 4000 patients),
ovanan (two ICON trials, each 2000 patients), prostate
(PRO6, 1800 patients), bladder (BA06, 1000 patients) and
oesophageal cancer (OE02, 1000 patients), and even larger
trials are being planned, e.g. of lung cancer (9000 patients).
Protocols for these studies are available from MRC Cancer
Trials Office.
The UK register of randomised cancer trials (Fayers and
Armitage, 1993) currently lists 504 UK trials, and shows that
75% of trials which commenced before 1985 contained fewer
than 430 patients. However, during 1985-89 this number
had increased to 500 patients, and since 1990 it has increased
again to 600 patients. However, there is no room for compla-
cency. There are still many trials which appear to be initiated
with scant regard for sample size. Since 1990 one in eight of
the registered 98 trials has aimed for 50 or fewer patients per
treatment arm.
Reporting of trials
A well-designed trial will have formally estimated the
required sample size and will have recorded the power cal-
culations. Awareness of the importance of these has led to
increasing numbers of medical journals demanding that full
details be published with reports of trials. Thus the statistical
guidelines for authors submitting papers to the British
Medical Journal (Altman et al.. 1983) state 'Authors should
include information on ... the number of subjects and why
that number of subjects was used'. and the accompanying
check list for referees (Gardner et al., 1986) asks 'was a
pre-study calculation of required sample size reported?'. One
important point arises from this last quote: the calculations
should be made 'pre-study'. Some studies are initiated with-
out adequate estimations of power and. especially when there
is 'no significant difference'. it is common for post hoc power
calculations to be requested by referees and editors, or even
by writers of subsequent correspondence. Unfortunately, as
recently discussed by Goodman and Berlin (1994), 'Although
several writers have pointed out the error implicit in the
concept of post hoc power. such caveats have not had great
impact'. The issues involved are subtle and rather complex,
and to some extent remain controversial. The principal is
that, whilst power calculations are vital to the design of a
good study, they are of limited value and arguably useless to
the subsequent interpretation of the single result that is
observed. Therefore, while we require assurance that the
study was well designed (pre-study power estimates), it is of
little value to calculate power retrospectively. This arises
from the logical inconsistency of applying pre-experiment
probabilities which relate to a hypothetical group of results
to a single result that is observed. The paper by Goodman
and Berlin explains the problem in clear terms, and builds
upon an analogy of 'trying to convince someone that buying
a lottery ticket was foolish (the before experiment perspec-
tive) after they have hit the jackpot (the after-experiment
perspective)'. Goodman and Berlin conclude 'avoid post hoc
power estimates entirely', and recommend the use of
confidence intervals and Bayesian estimates of treatment
effects for study reporting.
Two points are incontestable. Firstly, sample size and
power calculations should always be carried out before the
investigation commences, with reports stating how and why
they chose that number of subjects to study. Secondly, there
is little value in a post hoc calculation which takes the form
of, for example, 'we observed a difference of 14% which was
not significant; however, the power of detecting a difference
of 14% or greater for our sample size would have been
<50%'; it can be shown that such statements are
tautological, and the post hoc power corresponding to a
non-significant difference is always <50%! (Goodman,
1992).
Confidence intervals for interpreing and reporting results
The problems of interpreting power calculations in the con-
text of observed differences can be largely avoided by greater
use of confidence intervals. Investigators often have prior
beliefs concerning the results that they expect to observe, and
when a difference is not statistically significant such beliefs
may manifest themselves by comments such as 'the result was
not significant because there was too little power to detect
small differences'. While it may be true that the study had
little power to detect a real difference of the magnitude of the
observed one, the apparent implication that the observed
difference is a reliable indicator of the magnitude of the real
one is unfounded. The observed difference is more suitably
summarised by presenting confidence intervals, indicating the
range of values within which the true treatment difference islikely to Lie. This shows, far more informatively than com-
ments about power, the impact of sample size upon the
precsion of an estimate of treatment effect. It is reassuring to
note the increasing use of confidence intervals in medical
journals, suppemienting the use of P-values and reporting of
power calculation.
of sample ize a D power
Having discussed the importance of etimating sample size
and power, we are led to the question of how best to do it,
and the practical difficulties that arise. In this paper we
choose to focus most of the upon mple
considerations for a cancer therapy trial which is comparig
two treatments with respect to differences in the survival of
the patients. We do this because (a) such trials are espeially
common in the field of clinical ancer rsarch and (b) most
of the difficulties which are paricuLly appaent in this
setting are equally vald the context of other studies. Thus
we assume a trial in which patients are randomly alloated
either to a standard or control treatment, or to a new
treatment We also lmit discussion to trials which are seek-
ing to establish a treatment benefit; there are additional
considerations to take into account when a trial
which aims to establsh treatment equivaklnc (Stenning and
Alman, 1994). In estmatng the number ofpatients required
for a study (sample size), it is usual to identify a single major
outcome which is regarded as the primary end point for
comparing a treatment difference. In many clnical tials this
will be a measure such as survivaL response rate, time to
relapse, degree of palliation or a quality of life index. Some-
times there is more than one outcome and all are regarded as
of equal importance; this is dicussed below.
It is customary to start by specifying the size of difference
that it is desired to detect, and then to estimate the number
of patients that is required to enable the trial to detect this
difference if it really exists. Thus, for example, it might be
anticipated that a new treatment could improve 5 year sur-
vival from 20% of patients (old treatment) to 28% (new),
and that, since this is a plausble and meically important
improvement, it is desire to be reasonably of detect-
ing such a large difference if it really exists. 'Detecting a
difference' is usualy taken to mean 'obtain a statistically
significnt difference with P<0.05'; and milarly the phrase
'to be reasonably certain' is usualy interpreted to mean
something like 'have a chance of at least 90% of obtaining
such a P-value' if there really is an improvement from 20%
to 28%. The last statement corresponds, in ti l terms,
to saying that the power of the trial should be 0.9. It is
common to design trials requiring a power of 80% or 90%.
For a survival study, providing the survival curves are likely
to be approximately exponential, these four details (por-
tion of survivors in the control arm, difference in survival
proportions, signnce kvel, power) sffice to enable the
required sample size to be etimated
N_er of paies or a of death?
When designing a clinical trial, it is customary to express the
size requirements of the trial in terms of the number of
patients that it is desired to recruit. However, the required
size is really determined by the number of 'events' (for
example, deaths) that arise. To see that this must be so,
consider the folowing two extreme situations. Firstly, sup-
pose all patients have been recruited to the triaL but that no
deaths have occurred; ckarly we cannot esimate the relative
survival rates, and have no information upon which to base
the comparison of treatment groups. Secondly, suppose all
patients have been reruited, and that all have died; in this
cas, we have full information about the survival curves for
the patients entered into the trial, and their possible
treatment-related differences. Hence the information about
the survival curves is contained in the deaths ('events'), and
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the objective in designing a trial with a large number of
patients is simply to increase the number of deaths that we
expect to observe.
The matheatcal equations which enable us to estmate
the number of patients required in a survival study are,
therefore, based upon first estimating the number of events
required; the number thus obtained is then used to ulate
the number of patients expected to produce these events, by
assuming that patients enter the study in a systematic manner
and die at a steady rate. The distinction between patients and
events is important, and one that is often overlooked when
simply ding off'number ofpatients required' from sample
sie tables. Many protocols, too, merely state the number of
patients required in order to be able to detect the target
difference with reasonable certainty, and omit to iicate that
the number of patients has been derived indirectly and is
based upon having calulated the number ofdeaths that were
estimated to be necessary.
Exarn~pk
Calculations for the MRC STOl trial, based upon the details
given arlier, indicate that 135 'events' per treatment group
are required in order to obtain the desired power. The state-
ment '400 patients (200 per treatment arm) are required' was
an estimate of the number of patients that is required in
order to accrue 270 deaths by the time the data will be
analysed.
r of aaY_s*
Important consequences arise from the distinction between
number of patients and number of events. Even though the
specified number of patients may have been recruited to the
trial, the intended power will only be attained by waiting
until the required number of deaths have accrued. Thus, the
analyses for a clnical trial designed to have a partficular
power kvel should take place at a particular time; too soon,
and the lack of events will cause a loss of power-, too late,
and unn eary extra power will be yielded. Also, if fewer
deaths were observed than anticipated, either the sample size
should be increased by entering additional patients or
analysis of the results should be delayed until the necesary
deaths are observed.
Most tables for the number of patients in a log-rank test
(e.g. Freedman, 1982; Machin and Campbell, 1987) assume
that the patient acual is at a constant rate, so that the
median kngth of follow up is equal to one-half the accual
period plus the length of the post-accrual period (Freedman,
1982; Haybittle et al., 1990).
In practice, there will be an accrual period and then a
follow-up period; usually one estimates the baseli survival
rate and the anticipated survival rate for the treatment
groups as the expected survival probabilities for a given
median length of follow-up at the time of the intended
analyse. In the case of a tril involving treatment for poor-
prognosis disease, the median duration of follow-up may be
short since the events happen rapidly. However, the MRC
has this year launched a trial (PR06) in early prostate cancer
in which the prognosis is favourable; therefore analyses will
have to be deferred until patients have a medLian follow-up of
10 years, at which time 75% or more of patients are still
expected to be alive and metastases free.
Exarnpk
Intenm analysis of the STOI tral suggested that the baseine
(RI) survival may be 27% at 5 years, instead of 20% as
expected initially, thus fewer events would be accrued by the
planned date of analysis, which was at 5 years' median
duration of follow-up. There are several reasons why this
might be so: not all patients are entered into clinical trials,
and those recruited to ST01 may have been healthier than
anticipated; medical care may have changed over the years;Smmgi.Sim h .mm - q m mcuswe
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cases may be diagnosed earlier. However, as is often the case
with survival studies, at the time of the interim analysis few
patients had reached 5 years and so the estimate of 27% was
based upon very small numbers. Hence, the estimate had a
wide confidence interval, and a true rate of 20% was still
plausible. In the event, the steering committee for this trial
decided not to continue patient accrual beyond the planned
400. Instead, if necessary, analysis of STOI will be delayed
until sufficient deaths have been accrued.
Suppose, however, that 27% is the true baseline survival
rate, and that the data would be analysed at the time plan-
ned. Calculations show that the power to detect 41a% survival
rate (absolute percentage improvement of 14%) in the R2
arm would have fallen to 87%. Such a small reduction in
power is probably unimportant, but if it was really felt
necessary to maintain 90% power the recruitment could have
been extended to 450 patients.
Predsion
We have already indicated that, to estimate sample size for a
survival study, one must specify the baseline survival rate, the
treatment difference that one seeks to detect, the significance
level for the test and the desired power of the test. But all
these variables either can be difficult to determine with
precision or are totally subjective. There is nothing special
about a 5% P-value, as opposed to a 5.1% or a 4.9%
P-value; and the distinction between 90% power or 89%
power is likely to be of little practical relevance. Similarly
one might, for example, specify that a trial should be able to
detect a 20% difference in median survival; presumably a
19% difference is of almost equal interest, and the
specification of 20% is therefore a purely arbitrary value.
Thus, it is ofinterest to conduct a 'sensitivity analysis', which
can show the effect of varying the initial requirements. Some
of the better computer programs for sample size estimation
provide graphical support for displaying the results of sen-
sitivity analysis.
Here, however, we will focus upon one particular aspect,
namely sensitivity analysis of the difference that it is desire
to detect. Suppose 10% of patients are expected to survive to
5 years, and we wish to detect an improvement to 20%.
Figure I shows that we would require approximately 200
patients per group. But suppose we decide this is an
unreasonably optimistic difference to seek - few
chemotherapy trials seem to produce so great an improve-
ment; perhaps 17.5% is a more realistic target. Now we need
over 300 patients per group (since p -P2= 0.075). Or maybe
15% (p-p2=0.05) should be the targt: 600 patients per
treatment group! Thus, it is apparent that even smnall changes
in the input variables can result in dramatic variations in the
sample size estimates. It is rarely of any relevance to quote a
precise estimate of the number of patients required, and it is
customary to liberally round any estimates upward, as was
done in the STOI example when 185 patients per group was
rounded up to 200 patients.
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Fwe I Sample szes required to detect survival differences
P,-P2, for 90% power and 5% P-value.
Size of eces
The estimated sample size that is required might be written in
a statement such as 'to be 90% certain of detecting a treat-
ment difference oftd or greater, with a 5% signince lvel,
we require ... patients'. Thus, in order to estimate sample
size and power, one must first identify the magnitude of the
difference that it is wished to detect.
Sometimes there is prior knowledge which enables an
investigator to predict what treatment benefit is likely to be
observed, and the role of the trial is to confirm the expecta-
tions. At other times it may be possible to say that, for
example, only a doubling of median survival would be
worthwhile because the new treatment is so toxic and expen-
sive. In such cases the investigator may have definite opinions
about the treatment difference that is pertinent to detect.
However, very frequently, there is no obvious specific treat-
ment benefit that is sought. It may be that even a small
treatment benefit is regarded as important; for example, in
survival studies any improvement in survival rates may save
many lives if the disease is a common one. Thus, there will
have to be discussion about the magnitude of detectable
differences and the sample size. One suspects that in practice
a form of iteration is often used. A clinican might specify a
clinically useful difference that it is hoped could be detected,
and would then estimate the required sample size. Perhaps
we wish to be reasonably certain of obtaining a 'significant
P-value' if the survival advantage to a new treatment is 5%
at 2 years. The calculations might then indicate that an
extremely large number of patients is required. The investi-
gator may next say 'suppose we aim to be reasonably certain
of detecting a rather larger difference, say 10%'; the calcula-
tions are repeated, and perhaps the sample size is still too
large for the trial to be feasible. Perhaps the investigator is
willing to accept a power of 80% as being 'reasonably certain
of obtaining a 5% P-value'; the calulations are repeated
again. Also, the investigator might say: 'we can only recruit
500 patients within a reasonable number of years; what
differences can we detect with that sample size?. Eventually,
by iteration and compromise, either there is agreement con-
cerning the number of patients and the differences that can
be detected or the investigation must be deemed not feasi-
ble.
Some cinial trial protocols openly indate their un-
cert4inty; thus the MRC head and neck cancer protocol
(CHART, protocol available from MRC Cancer Trials
Office) states: 'we require 460 patients to detect an improve-
ment from 45% to 60%, 263 patients to detect an improve-
ment from 45% to 65% ... Given these considerations (and
assuming a loss to follow-up of 10%) we shall aim to recruit
500 patients into this study'.
One additional problem is that investigators are often
optimistic about the effect of new treatments; it can take
considerable eflbrt to initiate a trial, and so in many cases
the trial would only be launched if the investigator is
enthusiastic about the new treatment and is sufficiently con-
vinced about its potential efficacy. The experience of many
trials offices would seem to be that as trials progress there is
often a growing realism that, even at best, the initial expecta-
tions were optimistic. To some extent clinicians' optimism is
likely to be tempered by the cynicism of statisticians in trials
offices, for there is ample historical evidence to suggest that
trials which set out to detect large treatment differences
nearly always result in 'no significant difference was detect-
ed'; in such cases there may have been a true and worthwhile
treatment benefit, but the level of detectable differences was
set unrealstically high and thus many trials have been under-
powered.
Another issue, discussed later, is the crucial distinction
between the plausible differences that might be present and
the miniymlly worthwhile difference.
Example
The MRC trial of gastric surgery, STOI, was designed by
Laurence Freedman in -1985, and is exceptional in the carethat was taken in its sample size estimation. Eight surgeons
and clinicians, who were experienced in the treatment of
gastric carcinoma. were individually interviewed, and another
18 were sent postal questionnaires. They were asked about
what they expected to be the survival rate in the control
group. what difference in survival might be anticipated for
the aggressive alternative therapy and what difference would
be medically important and could influence their future treat-
ment of patients. Few other trials have been designed with
such care. On the basis of the opinions expressed, it was
decided to seek to detect a change in 5 year survival from
20% (RI surgery) to 34% (R2 surgery). However, it has
become apparent that over the last 7 years surgeons have
modified their views about R2 surgery, and now believe that
14% difference is too optimistic. Therefore, before the trial
was closed and before any survival information was revealed
to the steering committee, there was discussion of what
difference might be plausible and yet still worthwhile. The
prevailing consensus opinion is now that a 10% or even 8%
difference would be more realistic, and that this would still
represent a sufficiently large difference to influence future
surgical practice. If the calculations are repeated on the basis
of 27% survival in RI and 37% in R2 (an improvement of
10%), over 800 patients would be required. An improvement
of 8%, to 35% in R2, would require 1260 patients. This is
more than three times as many patients as in the STOI trial,
and at present recruitment rates would require another 14
years of patient accrual! In the event, it was decided not to
extend patient recruitment; a parallel trial was conducted in
The Netherlands, and a meta-analysis of the two trials is
planned.
Is sample size estimation worthwhile?
We have discussed a number of problems in deciding what
values to use for baseline survival and worthwhile detectable
differences, and have shown how sample size and power
calculations are greatly influenced by the precise values used.
Also, the STO1 trial is an example of how even the most
carefully planned trials may be based upon estimates which
with hindsight are very suspect - even though they were
based upon the best available information at the time the
trial was designed. One might therefore be tempted to ques-
tion the value of sample size estimation - is it ever possible
to obtain meaningful estimates of sample size? Fortunately,
however, this trial is in many ways atypical and has been
deliberately chosen so as to highlight the potential problems.
Frequently there will be pnror information and past experi-
ence concerning baseline survival rates and the likely
difference that might apply to the new treatment. As dis-
cussed below, when such information is not available, pilot
studies may offer one way forward. Also, by calculating
sample sizes for a variety of plausible baseline estimates and
differences, it is possible to obtain an idea as to whether the
proposed study is likely to be unrealistic.
In all cases, however, it is important to make the best
estimate that one can when planning a trial; the points that
we wish to emphasise in summary are that (a) it is futile to
regard estimates of sample size as precise when there is so
much uncertainty about the survival rates- they should be
treated with caution and usually rounded upwards; (b) sen-
sitivity analysis can be revealing at the design stage, and
power implications should also be reviewed at later stages in
the trial and when it is analysed; and (c) one should be
circumspect about the whole procedure of estimating sample
size. Despite these difficulties, however, it is essential to
perform sample size calculations before the start of a tnral.
Assmptons underlying sample size estimates
Estimates of sample size and power are based upon similar
assumptions to significance tests; in fact, in order to be able
to make these estimates it is necessary to specify in advance
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the methods of analysis that will be used. Thus for survival
analysis it is necessary to specify. before performing the
sample size calculations, what significance test will be used.
Two commonly used methods of analysis are the log-rank
test and tests based upon Cox or similar models. The Cox
model explicitly assumes what is known as exponential sur-
vival curves with proportional hazards; however, although
the log-rank test does not make the same assumptions. the
estimate of power associated with the log-rank test does
depend crucially upon the same assumptions. Thus, it is
important to consider whether these assumptions are valid
for any particular study and what the effect is of violation of
assumptions. Particular examples of violation might be: (a)
survival curves in which the hazard rate changes. for example
where there is an initial high post-operative risk following
surgery. or a reduced death rate for the duration of a
chemotherapy treatment, followed bv a different death rate at
later stages: (b) survival curves might cross over. for example
when initial aggressive therapy causes early deaths but imp-
roves survival rates in later years: (c) if one treatment 'cures'
a proportion of patients. while other patients continue to die
according to the initial death rate. In such cases the log-rank
test may not be optimal and the Cox model is likely to be
inappropriate: sample size estimates will need to take into
account the departures, which will frequently necessitate a
larger sample size.
It seems likely that the fundamental assumptions are fre-
quently violated. Minor departures mav have little effect
upon power. If a major deviation is anticipated. there should
be an adjustment to the sample size estimates. Various
models have been proposed. each dealing with particular
types of departure from assumptions. Often, however, there
is insufficient prior information about the precise shape of
the survival curves, and adjustments to sample size rely
greatly upon statistical experience.
Example
In the MRC STOI trial. the consensus surgical view is that
the survival rates following RI surgery are likely to be ap-
proximately exponential. but following R2 surgery there will
initially be a higher risk of post-operative mortality, followed
by an exponential survival curve until about 3-4 years. and
finally those patients who reach 4 years are likely to have
been 'cured', which will cause the R2 survival curve to flatten
out and cross the RI curve. However, the R2 survival curve
remains highly speculative and it is difficult to use these prior
expectations for power calculations.
Nomogram
One very simple means of estimating sample size while also
obtaining a feel for the sensitivity of the results to variations
in the specified factors is to use a nomogram. Figure 2.
described in the appendix, presents a nomogram for the
log-rank test. It is very easy to perturb a straight edge so as
to see the effect of varying the hazard ratio or the baseline
hazard. It is also difficult to read an exact value for sample
size from a nomogram; we would maintain that this inability
is an advantage over using tables, in that it forces one to be
more aware of the inherent imprecision of the numerical
estimates. A nomogram provides as much precision as is
appropriate for designing a tnral. Finally, a nomogram like
this summarises onto one sheet the equivalent of several
pages of tables.
More than one primary outcome
It is implicit in the above discussion that there is a single
identifiable end point or outcome upon which treatment
comparisons are based. Sometimes there is more than one
end point of interest. such as survival, response rates and
quality of life scores. If one of these end points is regarded asSa0ls sUE PM Fayers and D Machi
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more important than the others, it can be named as the
primary end point and sample size estimates caklulated
accordingly. A problem arises when there are several out-
come measures which are all regarded as equally important.
A commonly adopted approach is to repeat the sample size
estimates for each outcome measure in turn, and then select
the largest number as the sample size required to answer all
the questions of interest
Here, as with the discussion ofviolation of significan test
assumptions, it is essential to note the relationship between
significane tests and power: it is well recognised that P-
vahles become distorted if many end points are each tested
for signifi, and that adjustments should be made. Often
a smaller P-vahle will be considered necessary. In such cases,
the sample size calculations will be similarly affected.
A similar situation may be observed in a clinical trial
which compares three or more treatments; two common
methods of analysis are either to consider all pairwise com-
parisons (for example, four treatment arms would result in
six pairwise comparisons), or to use a global statistical tech-
nique such as analvsis of variance. In either cas, the sample
size calulations should reflect the itended method of
analysis.
Are smaDl triak of my vake?
In the context ofthis paper, a 'small trial' refers to one which
is too small to have a reasonable chance of detecting any
plausible difference, that is a trial with low power and which
is Ulkely to yield a non-significnt P-value even when the
hypothesise treatment difference really aeists. On the face of
it, such small trials are worthkss. There are, however, two
opposing schools of thought. At one extre, it can be
claimed that, whenever a clinician has any doubts about the
merits of two alternative treatments, the allocation should be
randomised. It is always better to conduct a randomised trial
and try to gain more scentific knowledge about the treat-
ments than to let patients be treated in a hapha imanner
according to the clinicians' w.ims. It is often sug d that
small trials are better than no trial at all, because their results
may well be of value when combined with data from other
sources, as in an overview or meta-analysis. At the other
extreme, however, the counter-argument maintains that most
improvements in cancer therapy are in themselves small
steps and small trials will never be able to detect such
differences. Small trials are therefore doomed to obtan
misleading results, caiming 'no difference' even when a
potentially very useful treatment advantage is in fact present.
Furthermore, if a small trial does obtain a sign t P-
value, the estimate of the treatment difference will almost
certainly be an overestimate, often a gross overestimate, but
with a wide confidence interval.
We hold a more mixed view. It is alvays preferable to aim
for a trial that has a reasonable chance of obtaiing a
meaningful result, that is to say a trial which has adequate
power to detect the difference of interest. However, if this is
not pracicable, we would accept that any trial is better than
no trial, provided two conditions are met
(1) All publications about the trial must make it clear that
the power was low, and that the results can at best be
regarded as hypothesis forming. Deeper interpretations
cannot be place upon either sign or non-signifi-
cance, even though the temptation is to be dismissive of
non-sign ('What can one expect - the sample size
was too small') and to attach too much importance to
signifiance (in a small trial, lacking power, a value of
P<5% will frequently indicate no more than that the
trWial is among the 5% which one expects to return
false-positive P-values).
(2) The trial, like all trials, should be registered before it is
commenced (Fayers et al., 1993; Fayers, 1994) so that,
kn
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I veven if it fails to be subsequently published, the results
will be known and available for use in overview or
meta-analyses. The existence of publication bias has
been well established (Simes, 1986; Dickersin et al.,
1987; Newcombe, 1987; Begg and Berlin, 1988; Dicker-
sin and Min, 1993); lar trials are likely to be pub-
ished, whereas small trials are more likely to be pub-
lished only if they have 'sgn t' results. Hence
preregistration of t is essential.
Fewer cotro
Sometimes, either becasue the total number of patients is
limited or because it is thought that the new treatment is
definitely supeior, there have been attempts to reduce the
number of patients in the control arm of a trial. The basic
arguments in favour of randomised trials and studies
based upon historical controls are old and well known (Chal-
mers et al., 1977; Pocock, 1983; Sacks et al., 1983; Gehan,
1984; Micciolo et al., 1985; Diehl and Perry, 1986). In
essence, historical controls carry risks of serious bias owing
to possible patient sekction bias, difences in resonse
criteria and changes over time. The references cited also
contain examples in which studis usng historical controls
have subsequently been shown to have resulted in biased
conclusions in favour of the new treatments. Of more inter-
est, however, is the work by Pocock (1976, 1983), which
considers usng a mixture of historical controls and ran-
domised controls, with more weight being given to the latter
group. The idea here is to use an unequal randomisation, in
which the majority of patients are randomised to the new
treatment, and to supplment the fewer randomsed controls
by combining them with the historical controls. Unfortun-
ately, the same inherent problems about historical controls
stiBl apply: not only wiBl the sample siz be too small to
pemit a sesitive comparison between historical controls and
randomised controls, but there remains the possibility that
the historical controls are not representative of current
patients and therefore seriously biaLed. Perhaps for these
reasons, such schemes do not appear to have been widely
adopted in clnical trials.
It is customary to design clinical trials with equal numbers
of patients in the two treatment arms; this is nearly opimal
in terms of obaining maximum power for a given total
smple size. (The p tive reader might note that since
survival comparisons obtain their information from deaths,
not patients, it would in fact be preferable to weight the
alocation ratio towards equal numbers of expected deaths in
the two treatment arms! However, under the null hypothesis,
we assume equal death rates for the two treatment groups.)
Although we would not recommend use of historical con-
trols, there may be many situations in which an unequal
randomisation ratio could be of value. It can be shown
statistically that if, for example, the randomisations are
weghted so that for every three patients allocated to the new
tratment there are two allocated to the control group, there
is very little impact upon the power to detect treatment
differences; by only slightly increasing the total sample size it
is possible to maintain the same power as for equal alloca-
tion ratios. Hence, if it is thought that there are reasons to
avoid usng the control therapy (such as serious sde-effects),
it is possible, with little increase in sample size, to allocate
the greater proportion of patients to the new therapy. One
example of such a trial is the MRC BRO6 protocol (available
from MRC Cancer Trials Offlice), which used a 2:1 allocation
ratio. This was done because primary CNS lymphoma is a
relatively rare cancer, and it was decided that there was
already sufficient knowld about the sadiar treatment,
radiotherapy, but that greater information was required
about adjuvant chemotherapy.
Pw _*es
In order to caculate the power or sample size of a trial, one
must first have available background information; for exam-
s - -- -
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pie, for a survival analysis one must know the expected
survival of the control or baselne arm. Also, one must have
some idea as to what is a realisic difference to seek. Some-
times such information is available as prior knowledge; at
other times, a pilot study may be conducted.
Traditionally, a pilot study is a distinct preiminary inves-
tigation, conducted before embarking on the main trial.
Recently, however, Wittes and Brittain (1990) have explored
the use ofan internal pilot study. The idea here is to plan the
clnical trial on the basis ofbest available information, but to
regad the first patients entered as the internal pilot. When
data from these patients have been collected, the sample size
can be re-esimated with the revised knowledge. Two vital
features accompany this approach: firstly, the final sample
siz should only ever be adjusted upwards, never down; and,
secondly, the authors ckarly explain why one should only use
the internal pilot in order to improve the estimation of
factors which are independent of the treatment variable. This
second point is crucial. It means that for a t-test one might
estimatethe variance, or for a survival comparison one might
stimate the survival of the control arm; in neither case
should the sample size be adjusted because of any apparent
differences tween treatments which might be observed dur-
ing the pilot phase. The reasons for the first point, only ever
adjusting upwards, are rather more subtle, but nonetheless
important. Both these points should be carefully observed,
however, to avoid distortion of the subsequent significance
test.
The advantage of an internal pilot is that it can be rela-
tively lawrg - for example, half the anticipated patients - with
no increase in time or money. It provides an insuance
against misjudgement regarding the baseline assumptions. It
is, however, important that the intention to conduct an inter-
nal pilot study is recorded at the outset and that full details
are given in the study protocol; otherwise there may be
suspicion that the invesugators performed multiple looks
before deciding to make ad hoc changes to the protocol.
The theoretical implications ofthis approach are still being
explored, but it would appear to place on a more scientific
footing a procedure which one suspects has sometmes been
instincvely yet covertly applied (and misapplied) by trallists
in the past.
C 's pior beiefs
The usual approach to sample size esumation requires
specfication of the size of difference that it is intended to
detect. However, this forces the clinan into a rather
artficial situation in which there is a simple cut-off where
one difference is regarded as realistic and ofmedical interest,
whilst a slightly smaller value is cLasified as of being of no
interest Furthrmore, it is likely that other clinicians would
have very different views as to what is the critical value of
interest Spiegebialter and Freedman (1986) have pioneered a
method of ssing cians' prior beliefs and expectations.
A fundamental aspect of this approach is that the null
hypothesis is no longer simply 'no difference' between the
treatments, but is dinical equivalec as determined by inter-
viewing the clinical participants. Specifically, participants and
other experts are asked 'what differences in survival rate
would infhence you to use treatment 1 or treatment 2?, and
could choose a range of values within which they would
remain uncertain which treatment to use; if, however, the
difference was more extreme in one direction they would
prefer to use treatment 1, whilst if it was more extreme than
the equivalence range in the other direction they would
choose treatment 2. This probably reflects clinical thinking
more closely than if one danded a single value for the
treatment difference, above whch treatment I is preferrd
and below which treatment 2 is favoured. This approach was
used in the MRC gastric trial, and most clinians indiated
that a 5-10% 5 year survival advantage to R2 would leave
them uncertain whether to use Rl or R2 surgery (because R2
surgery is accompanied by worse morbidity); some chose
10-15% as equivalent, and a few chose 10-20%.Sample si how mmany pabens are necessay?
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The clinicians were also asked to indicate what difference
in survival thev expected would emerge if many patients were
given the two treatments: they could indicate a range of
values, and weight their beliefs. For example. in the MRC
gastric trial. a clinician might have indicated that the 5 year
survival advantage to R2 surgery was probably more than
20%. and that it could be. but was less likely to be. above
25%, and that it could even be 30% or more. although this
would be even less likelv.
Spieglehalter and Freedman show that the information
collected in this manner can be used to examine how
different sample sizes affect the chance of reaching a firm
conclusion from the trial. which they call the 'predictive
power' or 'strength' of the trial. This emphasises one often
overlooked aspect of clinical trials. namely that the role of a
clinical trial should not be merely to establish treatment
differences. but should be to influence medical practice.
This method has proved extremely valuable for elucidating
clinicians' opinions and obtaining a general feel as to what is
the difference of interest. The authors noted that 'the clini-
cians frequently voice the opimnon that. although a difficult
exercise. it made them think deeper about the forthcoming
trial than they had done previously'. Unfortunately, it is
more difficult to incorporate the method into a formal proce-
dure for producing a single estimate of sample size, and its
value is rather more to enable graphical methods to display
the range of opinions and their effects upon sample size.
More recent work by Spiegelhalter et al. (1993) has extended
these interesting ideas.
Sequential trials
This article discusses conventional or 'fixed sample size' trial
designs. There are a number of other approaches which are
based upon sequential or repeated analyses of the accruing
data in the trial. Such designs do not specify a single sample
size, but typically use a predefined stopping rule; patients
continue to be entered until there is sufficient evidence either
that there is a treatment superiority or that there is unlikely
to be any difference between the treatments (e.g. Whitehead,
1992). Sequential designs may be appropriate when it is
important to terminate a trial at the earliest possible oppor-
tunity, either for ethical reasons (for example, to avoid
unnecessary deaths) or for financial reasons (cost of one
treatment arm). However, they depend upon having a rea-
sonable proportion of outcome results at the time of con-
ducting each interim analysis. For example, it would clearly
be impractical to consider a sequential scheme if the outcome
of interest is 5-year survival whilst the expected accrual
period for patients is only 3 years. Sequential designs also
depend upon having a single value of clinical importance.
whereas in practice there is frequently more than one.
Sequential designs remain controversial and are less widely
used than fixed sample size trials, possibly partly because of
their additional mathematical complexity and the need to use
computer software for the calculations. Some of the issues
involved are discussed by Fayers et al. (1994).
Prognostic factors
Sample size calculations for prognostic factors studies must
depend very much upon the method of analysis that will be
used for the modelling. However, many authors have noted
that far too often prognostic factor studies are absurdly
small, especially those in which survival is the outcome to be
predicted (e.g. Simon and Altman. 1994). Also, as always
with Cox models. sample size relates to the number of events
observed and not the number of patients; if the event rate is
low, the total number of patients must be increased accord-
ingly.
Simon and Altman (1994). in an earlier editorial, have
discussed statistical aspects of prognostic factor studies. As
they note. when the sample size is too small, there are
problems of multiplicity of testing which frequently result in
potential predictor variables being declared significant by
chance alone. The relative importance of the 'significant'
factors will also be unreliable. Claims for the predictive
accuracy of the prognostic equation are liable to be grossly
overstated. That a small sample size is a real practical prob-
lem can be readily observed: if one compares the many
published papers to be found describing prognostic factors
within a single disease area, it is common to find major
divergence of opinion as to the most useful factors - and
even as to which is the most important single factor.
Very little work has been done upon formal methods of
estimating sample sizes when evaluating prognostic factors,
although various authors have suggested rules based upon
intuition and experience. For example, Harrell et al. (1985)
suggest that. with half the data set being used for 'training'
and the other half reserved for subsequent validation of the
prediction equation, then 'as a rough rule of thumb one
should not attempt a stepwise (Cox) regression analysis when
there are fewer than ten times as many events in the training
sample as there are candidate predictor variables. The prob-
lems become more severe when one considers interaction
terms in the mode.'
Alternatively. Fielding et al. (1992) suggest that the proce-
dure for introducing a new candidate factor into existing
prognostic models should be 'first ... the prognostic relation-
ship will be evaluated in a study of several tens of patients
(e.g.. 50-100). If the results appear promising ... the results
will be studied on several hundreds of patients.' They also
note that, after a statistical model has been developed, its
validity should be verified from a separate data set; this
requires yet more patients.
A paper by Schumacher et al. (1994) investigates the use of
Cox models for evaluation of prognostic factors. They note
that prognostic factors should exhibit large relative risks if
they are to be useful, which might at first sight suggest that
smaller numbers of patients are required. Practical experience
combined with the results from their simulation studies lead
them to suggest that 'studies with less than 25 events per
factor cannot be considered as an informative and reliable
basis for the evaluation of prognostic factors.' Furthermore,
the relative risks and prevalence of each factor must be
considered. They conclude that small studies can at best only
serve to create exploratory hypotheses, and might lead to
misleading confusion; the large studies that are necessary will
often require collaboration between groups, or the use of
meta-analyses.
Schumacher et al. also describe a formula for sample size
when considering a single binary prognostic factor. However,
prognostic factor studies invariably involve a number of
factors, often including some with more than two levels. This
necessitates using a general multivariate form of the simpler
equation, and to solve this one would have to know the
multivariate distribution of the prognostic factors in advance,
which is not realistic (M Schumacher, personal communica-
tion). Thus, to a large extent one has to rely upon experience,
supported by simulation and some theory for some typical
situations.
Conclusions
Sometimes the estimation of sample size can be based upon
precise requirements accompanied by detailed information
about baseline rates and variability. Unfortunately, in our
experience, such situations are rare. All too often in clinical
trials and many other medical investigations there is a lack of
prior knowledge about what to expect from the study, mak-
ing sample size calculations fraught with difliculty. However,
despite the attendant problems, the estimation of sample size
and the consideration of power implications is of fundamen-
tal importance to the design of a sensible and realistic study
and should always be undertaken with the greatest of care.
Full details of the methods used to estimate sample size
requirements should be recorded. We note with approval thatSampk size: hw manypatent are necessary?
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such information is increasingly demanded by funding
bodies, independent protocol review committees, ethical
review panels, and, at the conclusion of the study, journals to
which reports are submitted.
Appenix A: Use of the nomogram
The left scale gives the power of the log-rank test corresponding to
P<O.O1 and P<0.05. The middle scale gives the total number of
deaths or events that it is required to observe. The right scale shows
the change in survival. presented as a percentage change in the
median or as the hazard ratio. If a straight edge is placed over
selected values on any two of the scales, the corresponding value
may be read off the third one.
For example. suppose we wish to detect a change from a median
survival of 10 months to a median survival of 15 months, and choose
to use a power of 90% and a 5% P-value. The change in median
survival corresponds to a 50% increase. Reading across the nomo-
gram suggests that the appropriate sample size is 260 events, or 130
per treatment gronup. If a power of 80% is acceptable. a total of 180
events would be required. whilst for 90 0 power and a 60% increase
in median survival just under 200 events are required.
Alternatively, if survival proportions x, and K2 are used instead of
medians, the hazard ratio is given by h = log(ic) log(wr9. and this is
also shown on the right-hand scale.
If x is the average survival proportion x = (Kl - K2) 2. then for e
events the number of patients can be estimated by e (1 - K).
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